{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '14.', 'DATA HANDLING AND RECORDKEEPING', '14.1.', 'Data/Documents', 'The Investigator must ensure that the records and documents pertaining to the conduct of the', 'study and the distribution of the investigational product are complete, accurate, filed, and', 'retained. Examples of source documents include: hospital records; clinic and office charts;', \"laboratory notes; memoranda; subject's diaries or evaluation checklists; dispensing records;\", 'recorded data from automated instruments; copies or transcriptions certified after verification as', 'being accurate copies; microfiche; x-ray film and reports; and records kept at the pharmacy, and', 'the laboratories, as well as copies of eCRFs or CD-ROM.', '14.2.', 'Data Management', 'Data will be collected via eCRF and entered into the clinical database per Amgen standard', 'operating procedures (SOPs). These data will be electronically verified through use of', 'programmed edit checks specified by the clinical team. Discrepancies in the data will be brought', 'to the attention of the clinical team, and investigational site personnel, if necessary. Resolutions', 'to these issues will be reflected in the database. An audit trail within the system will track all', 'changes made to the data.', '14.3.', 'Record Retention', 'Essential documents must be retained by the Investigator for a minimum of 2 years after the last', 'approval of a marketing application in an ICH region and until there are no pending or', 'contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the', 'formal discontinuation of clinical development of the IP. The Investigator must retain these', 'documents for the time period described above or according to local laws or requirements,', 'whichever is longer. Essential documents include, but are not limited to, the following:', 'Signed ICFs for all subjects;', 'Subject identification code list, screening log (if applicable), and enrollment log;', 'Record of all communications between the Investigator and the IRB/EC;', 'Composition of the IRB/EC;', 'Record of all communications between the Investigator, Amgen, and their authorized', 'representative(s);', 'List of Sub-investigators and other appropriately qualified persons to whom the', 'Investigator has delegated significant study-related duties, together with their roles in', 'the study, curriculum vitae, and their signatures;', 'Copies of CRFs (if paper) and of documentation of corrections for all subjects;', 'IP accountability records;', 'Record of any body fluids or tissue samples retained;', 'All other source documents (subject records, hospital records, laboratory records,', 'etc.);', 'Confidential and Proprietary', '66', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'All other documents as listed in Section 8 of the ICH consolidated guideline on GCP', '(Essential Documents for the Conduct of a Clinical Trial).', 'The Investigator must notify Amgen if he/she wishes to assign the essential documents to', 'someone else, remove them to another location or is unable to retain them for a specified period.', 'The Investigator must obtain approval in writing from Amgen prior to destruction of any records.', 'If the Investigator is unable to meet this obligation, the Investigator must ask Amgen for', 'permission to make alternative arrangements. Details of these arrangements should be', 'documented.', 'All study documents should be made available if required by relevant health authorities.', 'Investigator/Institution should take measures to prevent accidental or premature destruction of', 'these documents.', 'Confidential and Proprietary', '67', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}